GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Accumulated other comprehensive income (loss)

KalVista Pharmaceuticals (STU:4XC1) Accumulated other comprehensive income (loss) : €-3.02 Mil (As of Jan. 2024)


View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. KalVista Pharmaceuticals's Accumulated other comprehensive income (loss) for the quarter that ended in Jan. 2024 was €-3.02 Mil.

KalVista Pharmaceuticals's quarterly Accumulated other comprehensive income (loss) declined from Jul. 2023 (€-2.61 Mil) to Oct. 2023 (€-3.28 Mil) but then increased from Oct. 2023 (€-3.28 Mil) to Jan. 2024 (€-3.02 Mil).

KalVista Pharmaceuticals's annual Accumulated other comprehensive income (loss) declined from Apr. 2021 (€-1.20 Mil) to Apr. 2022 (€-3.58 Mil) but then increased from Apr. 2022 (€-3.58 Mil) to Apr. 2023 (€-2.79 Mil).


KalVista Pharmaceuticals Accumulated other comprehensive income (loss) Historical Data

The historical data trend for KalVista Pharmaceuticals's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Accumulated other comprehensive income (loss) Chart

KalVista Pharmaceuticals Annual Data
Trend Dec14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.71 -1.73 -1.20 -3.58 -2.79

KalVista Pharmaceuticals Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.29 -2.79 -2.61 -3.28 -3.02

KalVista Pharmaceuticals Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.


KalVista Pharmaceuticals Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


KalVista Pharmaceuticals (STU:4XC1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Accumulated other comprehensive income (loss)
Traded in Other Exchanges
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (STU:4XC1) Headlines

No Headlines